Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics

October 27, 2017

 

Unum Therapeutics to Present New Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, MA, October 27, 2017 --(BUSINESS WIRE)--Unum Therapeutics Inc.,

a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that the Company will be presenting on its Antibody-Coupled T cell Receptor (ACTR) platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held in Philadelphia, PA on October 27-30, 2017. The first poster presentation will highlight data from non-clinical studies on effective targeting of HER2-amplified cancers with trastuzumab used in combination with ACTR707, a novel Antibody-Coupled T cell Receptor (ACTR). The second poster will provide data from non-clinical studies on ACTR707 used in combination with rituximab, a novel T cell therapy for the treatment of relapsed or refractory CD20+ B cell lymphoma.

The accepted abstracts are listed below and are available online on the 2017 AACR-NCI-EORTC conference website: http://www.aacr.org/.

Presentation Details:

Title: Effective targeting of HER2-amplified Cancers with trastuzumab in combination with T cells expressing a novel Antibody-Coupled T cell Receptor (ACTR)
Authors: Katie M. O'Callaghan, John Shin, Eugene Choi, Greg Motz, Casey B. Judge, Heather A. Huet, Birgit C. Schultes, Seth A. Ettenberg
Authors’ Affiliation: Unum Therapeutics
Presenter: Katie M. O'Callaghan, Senior Scientist, Unum Therapeutics
Session: PO.A18 – EGFR/Her2
Session Date and Time: October 28, 2017, 12:30 - 4:00 PM
Location: Hall E, Pennsylvania Convention Center
Poster #: A163

Title: ACTR707: a novel T cell therapy for the treatment of relapsed or refractory CD20+ B cell lymphoma in combination with rituximab
Authors: Greg Motz, Kathleen Whiteman, John Shin, Tapasya Pai, Casey Judge, Anthony Barnitz, James Hemphill, James Kim, Ann Ranger, Heather Huet, Kathleen McGinness, Birgit Schultes, Geoffrey Hodge, Michael Vasconcelles, Seth Ettenberg
Authors’ Affiliation: Unum Therapeutics
Presenter: Greg Motz, Principal Scientist, Unum Therapeutics
Session: PO.B19 – Therapeutic Agents: Biological
Session Date and Time: October 29, 2017, 12:30 - 4:00 PM
Location: Hall E, Pennsylvania Convention Center
Poster #: B105

The posters will be posted on Unum’s website following the presentations.

About Antibody-Coupled T cell Receptor (ACTR) Technology
Unum’s proprietary ACTR is a chimeric protein that combines components from receptors normally found on two different human immune cell types – natural killer (NK) cells and T cells – to create a novel approach to cancer cell killing. T cells bearing the ACTR receptor protein can be directed to attack a tumor by combining with a monoclonal antibody that binds antigens on the cancer cell surface.

In contrast to other T cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum’s approach is not restricted by a specific tumor cell antigen and, thus, may have applications for treating many different types of cancers when combined with the right antibodies.

Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087 used in combination with rituximab, an anti-CD20 antibody, is Unum’s most advanced product candidate, currently in Phase I clinical testing for the treatment of adult patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma. The Company has two additional product candidates on track for imminent clinical testing under Investigational New Drug Applications (INDs) in effect with the FDA, ACTR707 used in combination with rituximab for the treatment of adult patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma, and ACTR087 in combination with SEA-BCMA for the treatment of adult patients with relapsed/refractory multiple myeloma.

About Unum Therapeutics
Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor indications. The Company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com/.

###

Media Contact:

Unum Therapeutics Inc.
Jeff Michaels, +1-617-843-3820
Corporate_Communications@unumrx.com